Clinical trials
Phase 2 trials in India with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 4 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 45 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tata Memorial Hospital | 6 |
| All India Institute of Medical Sciences | 3 |
| SVS Institute of Dental Sciences | 3 |
| Glenmark Pharmaceuticals Europe Ltd. (R&D) | 2 |
| Indian Council of Medical Research | 2 |
| Krishnadevaraya College of Dental Sciences & Hospital | 2 |
| Sanjay Gandhi Postgraduate Institute of Medical Sciences | 2 |
| Tosk, Inc. | 2 |
| 101 Therapeutics | 1 |
| Amai Charitable Trust | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus | 3 |
| Diabetes Mellitus, Type 2 | 3 |
| Head and Neck Neoplasms | 3 |
| COVID-19 | 2 |
| Mucositis | 2 |
| Oral Submucous Fibrosis | 2 |
| Periodontitis | 2 |
| Squamous Cell Carcinoma of Head and Neck | 2 |
| Tongue Neoplasms | 2 |
| Uterine Cervical Neoplasms | 2 |
Trials
Showing 1 to 25 of 45. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.